Kornimate/medical-research-clean huggingface dataset:
serological diagnostics of covid-19 in health care workers

Conditions: SARS-CoV Infection

Summary: all health care workers at the department of anesthesiology and intensive care at umc ljubljana will be tested for sars-cov2 with nasal swab test and blood withdrawal for sars-cov2 antibodies. at the same time a questionnaire with epidemiological anamnesis, risky contacts and the use of personal protective equipment will be fulfilled.

health care workers at the department of anesthesiology and intensive care at umc ljubljana are working with covid-19 patients in intensive care units, operating theaters, wards and emergency department. in the care of those patients different workgroups are involved: anesthesiologists, anesthesia and icu nurses and respiratory therapeuts.there is insufficient data on the seroprevalence in different workgroups, different areas of the hospital, insufficient data on connection between sars-cov2 nasal swabs and antibodies and the rate of asymptomatic infections. 300 hundred hcw will be tested for sars-cov2 with nasal swab test and blood withdrawal for sars-cov2 antibodies. at the same time a questionnaire with epidemiological anamnesis, risky contacts and the use of personal protective equipment will be filled.

Eligibility criteria:
inclusion criteria: * employee of department of anesthesiology and intensive care at umc ljubljana * active current employment at the department exclusion criteria: * current sick-leave

Keywords: sars-cov2 infection health care worker serology nasal swab tests anesthesiology and intensive care
electromyographic response to tsdcs in cnslbp

Conditions: Low Back Pain

Summary: the purpose of this randomized, double-blinded, sham-controlled study is to investigate the efficacy of trans-spinal direct current stimulation on pain level, quality of life, and electromyographic nociceptive flexion reflex in patients with non-specific chronic low back pain.


Eligibility criteria:
inclusion criteria: * individuals of both sexes. * age 18-60 years old. * chronic non-specific low back pain according to the most recent guidelines for the diagnosis and management of nslpb come from the american college of physicians and was published in 2017. according to these guidelines, the diagnosis of chronic nslbp should be made based on the following criteria: * chronic low back pain, defined as pain lasting for more than 12 weeks. * no specific identifiable cause of pain(e.g. infection, malignancy, fracture, inflammatory disorder). * no radicular symptoms(e.g. pain radiating down the leg). * no significant neurological deficits or findings on physical examination(e.g. loss of reflexes or muscle strength). exclusion criteria: * previous fractures and/or surgery in the vertebral spine. * neuropathic pain extending along the lower limb due to nerve root compression. * history of spine trauma or fracture. * implanted pacemakers. * pregnancy. * malignancy. * systemic musculoskeletal diseases. * epilepsy. * history of psychiatric disorders. * obesity
cd19 chimeric antigen receptor (car)-modified t cell therapy in treating patients with b-cell malignancies

Conditions: Acute Lymphoblastic Leukemia; B Cell Lymphoma

Summary: this is a single arm, open-label, phase 1/2 study to evaluate the safety and efficacy of anti-cd19 car-t cells in patients with relapsed or refractory b cell malignancies.

chimeric antigen receptor (car)-modified t cells (car-t cells) have the capabilities to recognize tumor associated antigen and kill tumor cells specifically. car-t therapy showed great effect on patients with relapsed or refractory b cell malignancies. car consists of single chain variable fragment (scfv) and activation domain of t cell. in preclinical study, the researchers constructed a second generation car containing cd137 costimulatory domain. this study aims to evaluate the safety and effectiveness of anti-cd19 car-t cells in patients with relapsed or refractory b cell malignancies.

Eligibility criteria:
inclusion criteria: 1. the patient is pathologically and histologically confirmed as cd19 + b cell tumors, and has no effective treatment options currently, such as chemotherapy or autologous hematopoietic stem cell transplantation (auto-hsct); or patients voluntarily choose cd19 car-t cells as a first treatment; 2. b cell hematological malignancies include the following three categories: * b-cell acute lymphocytic leukemia (b-all); * indolent b-cell lymphoma (cll, fl, mzl, lpl); * aggressive b-cell lymphoma (dlbcl, bl, mcl); 3. \< 70 years old; 4. expected survival time \> 6 months; 5. female patients around childbearing age, negative pregnancy test before trial, and agreed to take effective contraceptive measures during the trial until the last visit; 6. voluntarily participate in this experiment and sign informed consent by themself, or legally authorized representative. exclusion criteria: 1. with a history of epilepsy or other central nervous system diseases; 2. having graft-versus-host reaction, requires the use of immunosuppressants; 3. the presence of clinically significant cardiovascular disease, such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within recent six months, or heart disease with cardiac function in any grade 3 (moderate) or 4 ( severe) (according to the new york heart association (nyha) functional classification system); 4. pregnant or lactating women (safety of this therapy for the unborn child is unknown); 5. not curable active infection; 6. patients with active hepatitis b or hepatitis c virus infection; 7. combined use of systemic steroids within two weeks (except use of inhaled steroid recently or currently); 8. using product of gene therapy before; 9. creatinine\> 2.5 mg / dl (221.0 umol/l); alt / ast\> 3 x the normal amount; bilirubin\> 2.0 mg / dl (34.2 umol/l); 10. patients suffering from other uncontrolled diseases, and researchers believe that the patient is not suitable for trial; 11. patients with hiv-infection; 12. any situation that may increase the risk of patients or interfere with test results.
biventricular remodeling in transcatheter tricuspid valve replacement - acute hemodynamic instability study

Conditions: Tricuspid Regurgitation; Heart Failure; Structural Heart Disease; Interventional Cardiology

Summary: ttvr-ahi is a multicenter, retrospective registry including heart failure patients displaying a severe and symptomatic tricuspid regurgitation (tr), deemed non-eligible to cardiac surgery and therefore treated with transcatheter tricuspid valve replacement (ttvr) devices. this substudy of the main registry will focus on those with post-procedural acute hemodynamic instability (ahi).

ttvr-ahi is an international, multicenter, retrospective registry collecting routine clinical and echocardiographic data, on top of a dedicated analysis of the preprocedural ct-scan using laralab® software. patients with ahi will be compared to a control group without ahi, composed of individuals implanted with ttvr at columbia university irving medical center. in this substudy at columbia, the investigators aim to describe ahi incidence, its clinical presentation, its impact on prognosis, and the predictors of its occurrence.

Eligibility criteria:
inclusion criteria: * patients implanted with ttvr: evoque valve system (edwards lifesciences), and all other device in the setting of compassionate use and * patients presenting an ahi, defined by the need for inotrope and/or vasopressor support within 24 hours after the procedure due to hemodynamic instability (according to local investigator's judgement). exclusion criteria: * major procedural complication explaining hemodynamic situation (bleeding, tamponade, etc. ) * patients started on inotrope/vasopressor either as part of a routine post-interventional protocol or preventively for "right ventricular (rv) support" without sign of hypoperfusion.
evaluation of the pharmacokinetics, safety and tolerability of single dose of pf-06480605 in chinese healthy participants

Conditions: Inflammatory Bowel Disease

Summary: this is a phase 1, single-center, randomized, double-blind, third-party open (ie, participant blind, investigator blind and sponsor open), placebo controlled study to investigate pk, safety, tolerability, immunogenicity, and pd of pf 06480605 following a single subcutaneous dose of pf-06480605 450 mg and 150 mg (if needed) in chinese healthy adult participants.


Eligibility criteria:
inclusion criteria: * male and female participants must be 18 to 45 years of age, inclusive, at the time of signing the icd. * male and female chinese participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital sign and 12-lead ecg * bmi of 19 to 27 kg/m2; and a total body weight \>50 kg. exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). * history of hiv infection, hepatitis b, hepatitis c or syphilis; positive testing for hiv, hepatitis b, hcvab or serological reaction of syphilis. * history of allergic or anaphylactic reaction to a therapeutic drug. * history of recent active infections within 28 days prior to the screening visit. * participants with a fever within 48 hours prior to dosing. * history of tb or active or latent or inadequately treated infection. * recent exposure to live vaccines within 28 days of the screening visit. * a positive pregnancy test.

Keywords: ibd pk
to compare outcomes after transurethral enucleation of prostate versus transurethral resection of prostate

Conditions: Benign Prostatic Hyperplasia

Summary: the purpose of the study is to assess whether transurethral enucleation of prostate gives better or equivalent outcomes compared to the gold standard of transurethral resection of the prostate


Eligibility criteria:
inclusion criteria: * all who underwent turp or tuerp exclusion criteria: * those with prostate cancer, neurogenic bladder, previous urethral or prostate surgery

Keywords: bph
a trial evaluating the efficacy and safety of tenecteplase together with unfractionated heparin prior to early percutaneous coronary intervention (pci) as compared to standard primary pci in patients with acute myocardial infarction (assent 4 pci)

Conditions: Myocardial Infarction

Summary: to show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard pci (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute myocardial infarcts as compared to primary pci alone.


Eligibility criteria:
inclusion criteria: * patients giving informed consent * patients with a large acute myocardial infarction randomised within 6 hours of symptom onset * patients scheduled to undergo primary pci * patients reaching the cath lab not before 60 min and not later than 3 hours after randomisation (otherwise the patients fulfill the usual selection criteria for thrombolytic treatment and pci) exclusion criteria: none
development and clinical application of [11c]verapamil-pet

Conditions: Epilepsy

Summary: the major hypothesis explaining drug resistance is overexpression of p-glycoprotein at the target lesion. based on several studies, p-glycoprotein (p-gp) has an important role in neurologic diseases, especially in drug resistant epilepsy. but there is no surrogate marker that can quantify the expression of p-gp because of the difficulty in measuring substances in the neurologic system and the lack of clinical trials. here, the investigators use a novel non-invasive \[11c\] -verapamil brain pet and spam analytic method as a surrogate marker for quantifying the expression of p-glycoprotein.

a pilot study on healthy volunteers and a case-control study on patients with drug resistant epilepsy and drug sensitive epilepsy is performed. the investigators compare the whole brain suv in each group (normal control, drug resistant epilepsy, drug sensitive epilepsy) and the asymmetry by the standardized uptake value(suv) of ipsilateral areas and contralateral areas. \[11c\] -verapamil pet will be used as a surrogate marker of p-gp expression in patients with epilepsy, and will be an important prognostic factor of individualized drug therapy. also, it can be used as a biomarker in checking of the drug efficacy of novel medications. furthermore, by localizing epileptogenic zones for patients, \[11c\] -verapamil pet could contribute in improving the prognosis of surgical treatment in drug resistant epilepsy.

Eligibility criteria:
inclusion criteria: * healthy controls ( age range 20-45 years) * patient age (\> 15), diagnose as epilepsy exclusion criteria: * subjects who take medicines that affect on the function of p-glycoproteins * pregnancy or subject who feed the breast milk * subjects who had severe renal disease or liver disease * subjects who need treated by immunosuppressant or take immunosuppressant
pegfilgrastim pbpc mobilization study

Conditions: Lymphoma; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Hematology; Oncology

Summary: this is a randomized, double-blind, multi-center study to assess the safety and effectiveness of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily subcutaneous injections of filgrastim to mobilize stem cells for autologous transplantation in patients with hodgkin's or non-hodgkin's lymphoma.

this is a research study for hodgkin's disease and non-hodgkin's lymphoma (nhl) patients who will receive high-dose chemotherapy with autologous peripheral blood stem cell (pbsc or pbpc) transplant. the chemotherapy doses are high enough to severely suppress the bone marrow (where blood cells are made) and cause very low blood counts. a collection of stem cells (very young blood cells) followed by reinfusion to restore blood counts will be done to stimulate recovery of your blood counts. this procedure is called leukapheresis. giving growth factors to patients is a method to increase the number of pbpc that can be collected during leukapheresis. this process of giving growth factors to patients is called mobilization (moving cells from the bone marrow to the peripheral blood where they can be collected). the purpose of this study is to determine if pegfilgrastim, an investigational drug, can safely and effectively mobilize stem cells. filgrastim (also known as neupogen® or g-csf) is approved by the fda for stem cell mobilization. pegfilgrastim is a modified version of filgrastim that is longer acting.

Eligibility criteria:
* hodgkin's or non-hodgkin's lymphoma patients suitable for an autologous pbpc transplant - no previous bone marrow or pbpc transplant

Keywords: pbpc transplant hodgkin's disease non-hodgkin's lymphoma nhl mobilization
bioavailability of epa + dha enriched canned tuna and its acute effects

Conditions: Healthy Volunteers

Summary: evidence has suggested that omega-3 fatty acids, namely eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), have an important role in promoting cardiovascular health. however, the currently available scientific literature describing the postprandial effects and bioavailability of these fatty acids, particularly when they are incorporated into high protein food item, like canned tuna, is far from conclusive. the aim of this study is to evaluate the acute bioavailability of epa + dha enriched canned tuna and its acute effects on cardiovascular risk markers, in healthy human volunteers.


Eligibility criteria:
inclusion criteria: * adult men or women * age 18 - 59 years * willing to maintain usual diet and physical activity patterns * willing to comply with study protocol and procedures * willing to provide written informed consent exclusion criteria: * pregnant, breastfeeding or planning to become pregnant within the study period * subjects with current or previous cardiovascular disease (ischemic cardiovascular disease, angina stable or unstable; myocardial infarction, stroke or symptomatic peripheral arteriosclerosis) * subjects with liver or kidney diseases or cancer * diabetes mellitus (fasting glycemia\> 126 mg / dl) * uncontrolled hypertension (systolic blood pressure ≥160 mmhg or diastolic blood pressure ≥100 mmhg) * subjects with history of drug, alcohol or other substances abuse, or other factors limiting their ability to cooperate during the study * subjetcs with gastrointestinal disorder or under prescription for medication affecting gastrointestinal function or absorption of nutrients * known allergy (or sensitivity) to omega-3 fatty acids, fish (tuna), crustaceans, lactose or any meal ingredient * with antihypertensive therapy * health condition that prevents compliance with study requirements * subjects under prescription for medication for digestive symptoms such as anti-spasmodic, laxatives and anti-diarrheic drugs or other digestive auxiliaries * subjects under prescription of anticoagulant drugs * dietary patterns or supplement use that could interfere with study evaluations * subjects not willing to avoid the consumption of fish oil or food supplements, including fatty acids, during the study (except as indicated in the study protocol) * use of antibiotics in the last 4 weeks and laxatives in the last 2 weeks

Keywords: omega-3 fatty acids eicosapentaenoic acid (epa) docosahexaenoic acid (dha) bioavailability blood pressure lipid absorption canned tuna
/autism spectrum disorder(asd)hearing abnormalities study

Conditions: Autism Spectrum Disorder

Summary: co morbidity rates of hearing loss in children with autism spectrum disorder are high and increasing. investigators are aiming to: 1. evaluate peripheral auditory and brain stem auditory function in children with autism spectrum disorder. 2. compare communication capabilities in autistic children having hearing abnormalities and autistic children with normal hearing.

full audiological evaluation is carried out to all participants including: * pure tone and speech audiometry. * tympanometry and acoustic reflex threshold evaluation. * threshold auditory brain stem response for threshold determination in non co operative children not respond to pure tone,speech audiometry. * auditory brain stem response for neuro-otologic diagnosis. * transient evoked otoacoustic emissions in children proved to have normal hearing to detect minimal cochlear affection . * transient evoked otoacoustic emissions with contralateral masking. communication evaluation is carried out to all participants using arabic language test(kotby et al,1995). investigators use childhood autism rating scale for (cars) for diagnosis of autism spectrum disorder.

Eligibility criteria:
inclusion criteria: * children aged 3-12 years diagnosed to have mild to moderate autism spectrum disorder diagnosed by childhood autism spectrum disorder(cars 35% or less) exclusion criteria: * children with otitis media with effusion. * associated neurological deficit .

Keywords: hearing and communication abnormalities
telerehabilitation exercise: effects on maternal quality of life, fetal and neonatal health.

Conditions: Gestational Diabetes Mellitus in Pregnancy

Summary: gestational diabetes mellitus (gdm) occurs when blood sugar levels rise during pregnancy, typically between 24-28 weeks, affecting about 2-18% of all pregnancies. it is a common metabolic disease that can lead to health risks for the mother, fetus, and child, and can negatively impact the mother's quality of life. this study aims to explore how a telerehabilitation exercise program affects the quality of life of mothers with gdm and the health of fetus/neonate.

gestational diabetes mellitus (gdm) significantly impacts maternal quality of life (qol) and fetal/neonatal health. according to the world health organization, quality of life (qol) is a person's view of their status in life within their culture and value system. pregnancies with gdm, negatively affect personal, familial, and social life, leading to poorer qol. gdm causes medical issues for the mother and fetus and harms the mother's psychological well-being, reducing her qol. due to the increasing prevalence of gdm and the importance of improving qol for affected women, this study examines impact of telerehabilitation exercise on quality of life of pregnant women. awareness about the importance of exercise in managing gestational diabetes mellitus (gdm) is crucial. regular physical activity can help control blood sugar levels, reduce insulin resistance, and improve overall health for both the mother and fetus leading to better pregnancy outcomes.telerehabilitation offers convenience, accessibility, and personalized support, allowing patients to exercise from home with continuous healthcare provider monitoring.it is a cost-effective, flexible, and safer alternative to traditional exercise methods, especially beneficial for managing gestational diabetes. the control group will recieve routine medical care and the experimental group will recieve structured telerehabilitation exercise protocol. the results of both groups will be recorded and compared to assess the effectiveness of using telerehabilitation in the treatment of women with gdm in improving their quality of life.

Eligibility criteria:
inclusion criteria: * women aged 20 to 35 years * gestational age between 20-28weeks * diagnosed with gestational diabetes mellitus through oral glucose tolerance test (ogtt) * primigravida and multigravida * able to do 6 6-minute walk tests under a severity level of 6 on the borg scale of breathlessness. * patients or caregivers have and able to use an electronic device (pc, tablet or smartphone) * who signed informed consent exclusion criteria: * previously diagnosed t1dm or t2dm * high-risk pregnancy conditions contraindicating exercise as per acog guidelines * patients taking insulin regularly. * patients with fetal anomalies diagnosed at 20 th week. * multiple gestation (twin or triplets).
the relationship between training dynamics and general health status in veteran football players

Conditions: Football; Injury; Veteran

Summary: the goal of this observational study is to learn how training habits and general health status are related to injury risk in veteran football players (men over 35 years old who play recreational football). the main questions it aims to answer are: do specific training patterns (such as frequency, intensity, and duration) increase or lower the risk of injury? how does general health status (including factors like sleep, nutrition, and existing health conditions) affect injury risk? participants will: complete questionnaires about their training habits, lifestyle, and general health report any injuries they experience during the football season attend periodic health assessments


Eligibility criteria:
inclusion criteria: * playing football as a veteran exclusion criteria: * not participating in a regular training program

Keywords: fifa 11+ veteran football players injury risk